Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.

Benefits of attending include:

Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments

Key speakers include:

Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare

Plus an interactive pre–conference workshop
Tuesday 27th November 2012, The Copthorne Tara Hotel, London

Cardio-renal risk in type 2 diabetes information from clinical trials:
What we have, what do we need to know?

Workshop leader: Luigi Gnudi, Professor of Diabetes and Metabolic Medicine, Honorary Consultant in Diabetes and Endocrinology, Head, Unit for Metabolic Medicine, Cardiovascular Division, King’s College London
1.30pm-5.30pm

Register at http://www.smi-online.co.uk/goto/diabetes-conference15.asp
Alternatively contact Fateja Begum on tel: +44 (0) 20 7827 6184 or email: fbegum@smi-online.co.uk